Is gastrectomy indicated?

A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.  

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA
Sue Friedman
Executive director, founder, FORCE (Facing Hereditary Cancer Empowered)
Jon Florin
Executive director, chief patient advocate, No Stomach for Cancer
Table of Contents

YOU MAY BE INTERESTED IN

Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA
Sue Friedman
Executive director, founder, FORCE (Facing Hereditary Cancer Empowered)
Jon Florin
Executive director, chief patient advocate, No Stomach for Cancer

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login